IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook

UK's MHRA suspended Amgen's drug Tavneos for new patients, citing unreliable data in the main study. The regulator plans to revoke UK approval by March 2027. Amgen disagrees, citing additional clinical trial evidence. The European Commission also revoked approval in August. Amgen acquired the drug's developer, ChemoCentryx, in 2022 for $3.7 billion.

President Trump announced new voluntary drug pricing agreements with nine pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Merck, to lower U.S. prescription drug prices. The deals, part of the TrumpRx platform, aim to align prices with those in other wealthy nations. Companies receive tariff relief in exchange for participation. Critics note limited impact on patient costs and lack of public contract details.

Amgen (AMGN) reported that its drug Repatha reduced death risk by 20% in high-risk patients without prior heart attack or stroke, per Phase 3 trial data. The study, involving 12,000+ patients, also showed reductions in cardiovascular events. Repatha is approved in 75 countries and used by 9M patients globally. AMGN stock closed at $432.42 on Friday, up 0.95% in pre-market trading.

Amgen (AMGN) reported Phase 3 trial results showing its drug Repatha reduced mortality risk by 20%. The company offers a 2.3% dividend yield with a 44% payout ratio and a 7.1% 3-year growth rate. AMGN's stock trades 18.3% above its GF Value™ of $365.50, with a GF Score™ of 79. Insider activity shows $29.3M in sales, while institutional gurus show a slight net trimming trend.

Amgen (AMGN) reported that its drug Repatha reduced mortality risk in high-risk patients, per a clinical trial. The company offers a 2.3% dividend yield with a 44% payout ratio and a 7.1% 3-year dividend growth rate. AMGN's stock trades 18.3% above its GF Value™, with a GF Score™ of 79. Insider sales totaled $29.3M over the past year, while institutional investors show mixed sentiment.

Amgen reported that Repatha reduced death risk by 20% in high-risk adults without prior heart events, per Phase 3 trial data. The drug was used alongside statins or other LDL-C treatments.